ArriVent BioPharma, Inc.'s total assets for Q1 2025 were $215.50M, a decrease of -21.62% from the previous quarter. AVBP total liabilities were $12.95M for the fiscal quarter, a -25.08% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.